NEW YORK – Digital pathology firm PathAI announced on Thursday that it has entered a strategic collaboration with Cleveland Clinic to use PathAI's pathology algorithms for translational research and clinical diagnostic purposes.
Under the five-year agreement, the partners will digitize hundreds of thousands of pathology specimens across multiple disease areas, PathAI said in a statement. That data will be linked with clinical and molecular information from Cleveland Clinic to create a multimodal dataset to conduct research with PathAI's technology platform and algorithms. PathAI will use the data from the digitized slides to develop and improve its algorithms and the clinical information for research and validation purposes, it said.
The partnership also is intended to enable the development and usage of artificial intelligence-powered pathology diagnostics to improve patient care, Boston-based PathAI said. Cleveland Clinic's team will provide its expertise to ensure PathAI's algorithms are "fit-for-purpose in both clinical and research settings," the company added.
Financial terms of the deal were not disclosed, although the company said Cleveland Clinic will become an equity holder in PathAI as part of the agreement.